Table 1.
Baseline patient characteristics
| Variables | No, (%) |
|---|---|
| Age, year, median (range) | 67 (49.5–76.0) |
| Male gender | 39 (73.6) |
| Baseline ECOG PS | |
| 0–1 | 30 (56.6) |
| 2–3 | 23 (43.4) |
| Histology | |
| Squamous cell carcinoma | 27 (50.9) |
| Adenocarcinoma | 10 (18.9) |
| NSCLC-NOS | 6 (11.3) |
| Small cell carcinoma | 3 (5.7) |
| Sarcoma | 4 (7.5) |
| Renal cell carcinoma | 1 (1.9) |
| Lymphoma | 1 (1.9) |
| Endometrial carcinoma | 1 (1.9) |
| Tumor origin | |
| Primary lung cancer | 37 (69.8) |
| Metastasis | 16 (30.2) |
| Tumor size, cm, median (range) | |
| Compression part | 5.5 (4.1–7.2) |
| Invasion part | 2.0 (1.5–3.0) |
| Site of tumor | |
| Trachea | 9 (17.0) |
| Main bronchi | 28 (52.8) |
| Lobar bronchi | 16 (30.2) |
| Chemotherapy | |
| Platinum-based doublet | 25 (47.2) |
| Singlet | 12 (22.6) |
| BSC alone | 16 (30.2) |
| Overall survival | 13.0 (9.5–18.8) |
| Total patients | 53 (100) |
BSC, best supportive care; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC-NOS, non-small cell lung cancer not otherwise specified.